Vienna Insurance Group’s Nurix Therapeutics NRIX Stock Holding History

Vienna Insurance Group’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.32M	Hold	85,000	–	–	0.5%	25
2025 Q4	$1.61M	Hold	85,000	–	–	0.79%	23
2025 Q3	$785K	Hold	85,000	–	–	0.46%	23
2025 Q2	$968K	Hold	85,000	–	–	0.61%	24
2025 Q1	$1.01M	Hold	85,000	–	–	0.55%	78
2024 Q4	$1.6M	Hold	85,000	–	–	0.93%	20
2024 Q3	$1.91M	Hold	85,000	–	–	0.81%	26
2024 Q2	$1.77M	Hold	85,000	–	–	0.69%	29
2024 Q1	$1.25M	Hold	85,000	–	–	0.49%	86
2023 Q4	$877K	Hold	85,000	–	–	0.4%	90
2023 Q3	$668K	Hold	85,000	–	–	0.3%	90
2023 Q2	$849K	Hold	85,000	–	–	0.39%	87
2023 Q1	$755K	Buy	+85,000	New	+$886K	0.44%	53

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Vienna Insurance Group's NRIX Position: Q1 2026 in Review

Vienna Insurance Group held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 85,000 shares worth $1.32M. The position accounts for 0.5% of the portfolio, ranked #25.

Vienna Insurance Group first reported a position in NRIX in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.91M in Q3 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Vienna Insurance Group held 85,000 shares of Nurix Therapeutics worth $1.32M as of Q1 2026.
Vienna Insurance Group left its Nurix Therapeutics share count unchanged in Q1 2026.
Nurix Therapeutics made up 0.5% of Vienna Insurance Group's portfolio in Q1 2026, its #25 holding.
Vienna Insurance Group first reported a position in Nurix Therapeutics in Q1 2023 and has held it in 13 quarters since.
Vienna Insurance Group's Nurix Therapeutics position peaked at $1.91M in Q3 2024.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Vienna Insurance Group's 13F filing for Q1 2026, filed 5 May 2026.